CN117279951A - 抗5t4抗体及其用途 - Google Patents

抗5t4抗体及其用途 Download PDF

Info

Publication number
CN117279951A
CN117279951A CN202280032428.7A CN202280032428A CN117279951A CN 117279951 A CN117279951 A CN 117279951A CN 202280032428 A CN202280032428 A CN 202280032428A CN 117279951 A CN117279951 A CN 117279951A
Authority
CN
China
Prior art keywords
seq
ser
thr
gly
tyr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032428.7A
Other languages
English (en)
Chinese (zh)
Inventor
O·博金
L·达萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Leeson
Original Assignee
Immune Leeson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Leeson filed Critical Immune Leeson
Publication of CN117279951A publication Critical patent/CN117279951A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280032428.7A 2021-05-04 2022-05-02 抗5t4抗体及其用途 Pending CN117279951A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183636P 2021-05-04 2021-05-04
US63/183,636 2021-05-04
PCT/IL2022/050451 WO2022234570A1 (en) 2021-05-04 2022-05-02 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN117279951A true CN117279951A (zh) 2023-12-22

Family

ID=83932628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032428.7A Pending CN117279951A (zh) 2021-05-04 2022-05-02 抗5t4抗体及其用途

Country Status (11)

Country Link
US (1) US20240228658A1 (https=)
EP (1) EP4334362A4 (https=)
JP (1) JP2024517760A (https=)
KR (1) KR20240004837A (https=)
CN (1) CN117279951A (https=)
AU (1) AU2022270453A1 (https=)
BR (1) BR112023023086A2 (https=)
CA (1) CA3217716A1 (https=)
IL (1) IL308203A (https=)
MX (1) MX2023013018A (https=)
WO (1) WO2022234570A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183811A1 (en) * 2023-03-08 2024-09-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-5t4 antibodies and uses thereof
CN121002067A (zh) * 2023-04-03 2025-11-21 非同（成都）生物科技有限公司 抗5t4抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
SG11202008399QA (en) * 2018-03-12 2020-09-29 Genmab As Antibodies
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
US20240228658A1 (en) 2024-07-11
WO2022234570A1 (en) 2022-11-10
AU2022270453A1 (en) 2023-12-21
BR112023023086A2 (pt) 2024-01-30
EP4334362A4 (en) 2025-04-16
KR20240004837A (ko) 2024-01-11
CA3217716A1 (en) 2022-11-10
MX2023013018A (es) 2024-01-18
EP4334362A1 (en) 2024-03-13
IL308203A (en) 2024-01-01
JP2024517760A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
EP3353213B1 (en) Anti-mesothelin antibody and composition comprising the same
JP2024504471A (ja) Ｒｏｒ１およびｃｄ３に対する特異性を有する多重特異性抗体
EP4292611A1 (en) Anti-cd112r antibody and use thereof
TW202246323A (zh) 抗ｃｌａｕｄｉｎ—６之抗體及其用途
WO2023109888A1 (zh) 抗ang2-vegf双特异性抗体及其用途
CA3215704A1 (en) Antibodies binding trop2 and uses thereof
US20240228658A1 (en) Anti-5t4 antibodies and uses thereof
CN116134052A (zh) 多特异性抗体
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
EP4349867A1 (en) Specific binding protein targeting pd-l1 and cd73
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
EA053012B1 (ru) Антитела к 5t4 и варианты их применения
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2024184810A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
WO2025228298A1 (zh) 靶向TROP2xPD-L1的双特异性抗体药物偶联物及其制备方法与应用
HK40054516A (en) Novel mesothelin antibody and composition comprising the same
HK40054516B (zh) 新的间皮素抗体和包含其的组合物
HK40066347B (zh) 靶向 cldn18.2 的抗体及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination